Zusammenfassung
Während die Zahl der Alkoholabhängigen in den alten und neuen Bundesländern auf etwa 5 Mio. der Gesamtbevölkerung geschätzt wird, beträgt die Zahl der Heroinabhängigen etwa 120.000. Wegen der Dunkelziffer kann die Zahl jedoch auch gut doppelt so hoch sein [1]. Letztlich muss mit einer Zunahme der von dieser Stoffklasse Abhängigen gerechnet werden. Dies ist aus der Tatsache abzuleiten, dass, trotz Abnahme der Zahl der Drogentoten in den letzten Jahren, die Zahl an Erstkonsumenten harter Drogen rapide zugenommen hat (□ Abb. 33–1). Hierfür sind neben dem akuten Preisverfall und einer größeren Reinheit des angebotenen Stoffs auch neuere Analoga schon bekannter Opioide, sog. »Designerdrogen« (Modifikationen bekannter Opioide) mitverantwortlich, die sich durch eine höhere Wirkpotenz auszeichnen [2, 3].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literaturverzeichnis
Wahl C (1987) »Was Ihr wollt« - zur statistischen Einschätzung von Konsum, Mißbrauch und Abhängigkeit bei legalen und illegalen Drogen. In: Ness B, Wahkl C, Ziegler H (Hrsg) Jahrbuch zur Frage der Suchtgefahren. Neuland, Hamburg, pp 89
Henderson G (1988) Designer drugs: The new synthetic drugs of abuse. Clinical update in toxicology. Du Pont Pharmaceuticals, Delaware/WI
Sahihi A (1989) Designer-Drogen. Die neue Gefahr. Beltz, Weinheim Basel
Scheerer S (1989) Die Heroinszene. In: Scheerer S, Vogt I (Hrsg) Drogen und Drogenpolitik. Campus, Frankfurt am Main, pp 285–299
Christiani E, Stübing G (1972) Drogenmissbrauch und Drogenabhängigkeit. Deutscher Ärzteverlag, Köln
Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs. In: Martin WR (ed) Drug addiction, vol 1. Springer, Berlin Heidelberg New York, pp 197–258
Jasinski DR, Pevnik JS, Griffith JD (1978) Human pharmacology and the abuse potential of the analgesic bupre-norphine. Arch Gen Psychiatry 35: 501–516
Lewis JW, Walter D (1992) Buprenorphine-background to its development as a treatment for opioid dependence. NIDA Res Monogr 121: 5–11
Abbott A (1992) Neurobiological perspectives on drugs of abuse. Trends Pharmacol Sei 13: 169
Ramsey NF, van Ree JM (1992) Reward and abuse of opiates. Pharmacol Toxicol 71 /2: 81–94
DiChiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244 /3: 1067–1080
Thomas DN, Fontana DJ, Post RM, Weiß SRB, Pert A (1993) The involvement of the mesocorticolimbic dopamine system in the conditioned effects of cocaine. In: Harris L (ed) Problems of drug dependence. Proceedings of the 54th Annual Scientific Meeting 1992. NIDA, Rockville. Vol 260, PP 132
Wang Y, Bilsky E, Porreca F, Sadee W (1994) Constitutive p opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54: 339–350
Sadee W, Wang Z (1993) Constitutive fj opioid receptor activation can account for narcotic tolerance and dependence. Proceedings International Narcotics Research Conference (INRC). Uppsala Universitet Reprocentralen HSC, Skövde/Sweden, p 102
Piepenbrock S, Hempelmann G, Peters H (1977) Veränderungen der Hämodynamik der Herzinotropie und des myocardialen Sauerstoffverbrauchs nach Antagonisierung von hohen Dosen von Fentanyl mit Naloxon. Prakt Anästh 12: 275
Freye E, Härtung E (1982) Naloxone induces excitation of the cardiovascular system and a rise in myocardial oxygen consumption in fentanyl and meperidine-anesthetized dogs. Acta Anaesth Belg 33: 89–97
Höllt V, Przewlocki R, Herz A (1978) ß-Endorphin-like immunoreactivity in plasma, pituitaries and hypothalamus of rats following treatment with opiates. Life Sci 23: 1057
Goldstein DB, Goldstein A (1961) Possible role of enzyme inhibition and repression in drug tolerance and addiction. Biochem Pharmacol 8: 48–53
Zola EM, MacLeod DC (1983) Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intell Clin Pharm 17: 411–417
Cookson RF (1983) Carfentanil and lofentanil. Clin Anaesthesiol 1: 156–158
Langston JW, Ballard P, Tetrud JW, I (1983) I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Langston JW, Irwin J, E. B. L, Forno LSC (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225: 1480–1482
Freye E (1999) Opioide in der Medizin, 4. Aufl. Springer, Berlin Heidelberg New York Tokio
Freye E (1992) Medikamenteninteraktion bei der Metha-dontherapie. Z Ärztl Fortbild 86: 731–737
Schuster S, Weilemann LS, Meyer J (1989) Drogennotfälle. Notarzt 5: 23–28
Kreek MJ (1973) Medical safety and side effects of methadone in tolerant individuals. JAMA 233: 665–668
Kreek MJ, Khuri E, Flomenberg N, Albeck H, Ochshorn M (1989) Immune status of unselected methadone maintained former heroin addicts. In: Quiron R, Jhamandas K, Gianoulakis C (eds) The International Narcotics Research Conference (INRC) ‘89. Liss, New York. Progress in clinical and biological research, vol 328, pp 445–448
Latasch L, Schneider M, Steinau U (1986) Morphologische Befunde an Skelettmuskelbiopsien bei Heroinabhängigen. Klinikarzt 15: 252
McCammon RL (1986) Anesthesia for the chemically dependent patient. In: Review Course Lectures 1986. International Anesthesia Research Society (IARS), Cleveland, pp 47–55
Martin WR, Jasinski DR, Haertzen CA et al. (1973) Methadone–A réévaluation. Arch Gen Psychiatry 28: 286–295
Freye E, Schenk GK (1990) Methadon als Ersatztherapie beim Opiatabhängigen? Klinikarzt 2: 57–61
Mark LC (1966) Hypotension during anesthesia in narcotic addicts. N Y State J Med 66: 2685–2695
Martin WR, Jasinski DR (1977) Assessment of the abuse potential of narcotic analgesics in animal. In: Martin WR (ed) Drug addiction. I. Morphine, sedative/hypnotic and alcohol dependence. Handbook of experimental pharmacology, vol 45/I. Springer, Berlin Heidelberg New York
Dole VP, Nyswander ME (1965) A medical treatment for diacethylmorphine (heroin-) addiction. JAMA 193: 646–650
Winkler KR (1980) Zur Strafbarkeit des Arztes gemäß § 11 Abs. 1 Nr. 9 Betäubungsmittelgesetz. Suchtgefahren 26: 28–37
Rösinger C, Gastpar M (1991) Methadonsubstitution in der Behandlung schwerkranker Opiatabhängiger. Dtsch Ärztebl 44: C-2079-C-2088
Franke M (1985) Übergeordnete Gesichtspunkte zur Bewertung von Methadonprogrammen. Suchtgefahren 31: 95–100
Hartmann H, Uchtenhagen A, Fuchs W, Pasi A (1984) Hausärztliche Methadonbehandlung bei Heroinabhängigen. Schweiz Rundschau Med 73: 299–304
Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N (1976) Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 21: 147–157
Keup W (1978) Methadon-Erhaltungsprogramme. Dtsch Ärztebl 18: 1179–1182
Beaver WT, Wallentein SL, Houde RW, Roger A (1976) A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of orally administered methadone. Clin Pharmacol Ther 8: 415–426
Olsen GD, Livermore JD, Wendel HA et al. (1976) Methadone induced respiratory depression in female methadone maintenance subjects. Clin Res 24: 388 A
Brune K, Dietzel K, Möller N (1986) Pharmakologie des Schmerzes-Abhängigkeit, Sucht. In: Wörz R (Hrsg) Pharmakologie bei Schmerz. Edition Medizin VCH, Weinheim, pp 120–134
Nielsson MI (1982) Clinical pharmacokinetics of methadone. University Press, Upp sala/Sweden (Thesis )
lnturrisi CE (1973) Disposition of methadone in man after single oral dose. Clin Pharmacol Ther 13: 923–930
Nielsson MJ, Widerloev E, Meresaar U, nggard E (1982) Effect of urinary ph on the disposition of methadone in man. Eur J Clin Pharmacol 22: 331–342
Romach MK, Piafsky KM, Abel JG, Khouw V, Seilers EM (1981) Methadone binding to orosomucoid (alphal-acid-glucoprotein). Determinant of free fraction in plasma. Clin Pharmacol Ther 21: 307–321
Goldfrank L, Flamenbaum N, Weismann RS (1981) General management of the poisened overdosed patient. Part 1. Patients in coma with altered mental status. Hosp Physician 17: 24–62
Kreek MJ, Gutjahr CL, Garfield JN, Bowen DV, Field FH (1976) Drug interactions with methadone. Ann N Y Acad Sei 281: 350–370
Novick DM, Kreek MJ, Fanizza AH, Yancovitz SR, Gelb AM, Stenger RM (1981) Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 30: 353–362
Blinick G, Wallach RC, Jerez E (1969) Pregnancy in narcotic addicts treated by medical withdrawal. The methadone detoxification program. Am J Obst Gynecol 105: 997–1003
Rothstein P, Gould JB (1974) Born with a habit–Infants of drug addicted mothers. Pediatr Clin North Am 21: 307–321
Geber WF, Schramm LC (1975) Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. Am J Obstet Gynecol 12: 705–713
Gourlay GK, Wilson PR, Glynn GJ (1982) Pharmacodynamics and pharmacokinetics of methadone during the operative period. Anesthesiology 57: 458–467
Freye E (1987) Opioid agonists, antagonists and mixed narcotic analgesics. Theoretical background and considerations for practical use. Springer, Berlin Heidelberg New York Tokio
De Castro J, Viars P (1968) Utilisation pratique des analgésiques centraux en anesthésie et réanimation. Ars Med 23: 74–74
Liebson I, Bigelow G, Flamer R (1971) Alcoholism among methadone patients; a specific treatment method. Am J Psychiat 130: 483–485
Stimmel B, Hanburg R, Stuniano V, Korts D, Jackson G, Cohen M (1982) Alcoholism as a risk factor in methadone maintenance. Am J Med 73: 631–636
Chabalko J, La Rosa J, du Pont RL (1973) Death of methadone users in the district of Columbia. Int J Addict 8: 897–908
Schulte RM (1986) Medikamentenabhängigkeit und Poly-toxikomanie. Ergebnisse einer empirischen Untersuchung bei Drogenabhängigen und Alkoholikern. Dtsch Ärztebl 83: 3451
Olson GD, Bennett WM, Porter GA (1975) Morphine and Phenytoin binding to human plasma protein in renal and hepatic failure. Clin Pharmacol Ther 17: 677
Sifton DW (1988) Drug Interaction and Side Effects Index, Physicians Desk Reference (PDR) 42th Edn. Medical Economics Company, Oradell, N.Y.
De Castro J (1971) Association des analgésiques centraux et des neuroleptiques en cours d’intervention. In: Vourch G, De Castro J, Gauthier-Lafaye P, Guidicelli JF, Viars P (eds) Les analgésiques et la douleur. Influences pharma-cologiques diverses exercées sur morphiniques. Masson, Paris, pp 185–194
Freye E (1991) Opioide in der Medizin. Wirkung und Einsatzgebiete zentraler Anal getika, 2. Aufl. Springer, Berlin Heidelberg New York Tokio
Bewley TH, Ghodse AH (1984) Opiate analgesics and narcotic antagonists. In: Dukes MNG (ed) Meyler’s side effects of drugs, 10th Edn. Elsevier, Amsterdam, pp 120–134
Elstrom J (1977) Plasma protein binding of phenytoin after cholecystectomy and neurosurgical operations. Acta Neur Scand 55: 455
Gibaldi M, Perrier D (1975) Pharmacokinetics. Dekker, New York
Keup W (1983) Clonidin–seine Möglichkeiten in der Pharmakotherapie der Heroin abhängigkeit. Dtsch Ärztebl 80 /3: 25–32
Gold MS, Pottash AC, Sweeney DR, Kleber HD (1980) Opiate withdrawal using Clonidin. A safe, effective, and rapid nonopiate treatment. JAMA 243: 343–348
Groß A, Soyka M (1999) Buprenorphin–ein neuer Ansatz in der Pharmakotherapie opiatabhängiger Patienten. Suchtmed 1: 5–14
Kosten TR, Morgan C, Kleber HD (1992) Phase II clinical trials of buprenorphine: Detoxification and induction into naltrexone. NIDA Res Monogr 121: 101–119
Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J (1993) Buprenorphine versus methadone maintenance for opioid dependence. J Nev Ment Dis 181 /6: 358–364
Guthrie SK (1990) Pharmacologic interventions for the treatment of opioid dependence and withdrawal. Ann Pharmacother 24/7–8: 721–734
Bickel WK, Stitzler ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988) Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247 /1: 47–53
Woods JH, France CP, Winger GD (1992) Behavioral pharmacology of buprenorphine issues relevant to its potential in treating drug abuse. NIDA Res Monogr 121: 12–27
Bickel WK, Amass L (1995) Buprenorphine treatment of opioid dependence. A review. Exp Clin Psychopharmacol 3: 477–489
Fudala PJ, Johnson RE, Bunker E (1989) Abrupt withdrawal of buprenorphine following chronic administration. Clin Pharmacol Ther 186/2: IVB-1
Mello NK, Mendelson JH (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207: 657–659
Mendelson JH, Mello NK, Teoh SK, Kuehnle J, Sintavana-rong P (1991) Buprenorphine treatment for concurrent heroin and cocaine dependence: phase I study. NIDA Research Monograph Series 105, pp 196–202
Mendelson JH, Mello NK (1992) Human laboratory studies of buprenorphine. NIDA Res Monogr 121: 38–60
Auriacombe M, Franques P, Bertorelle V, Tignol J (1999) Use of buprenorphine for substitution treatment–a French experience in Bordeaux and Bayonne. Res Clin For 19: 47–50
Kosten TR, Morgan C, Kleber HD (1991) Treatment of heroin addicts using buprenorphine. Am J Drug Alcohol Abuse 17 /2: 119–128
Resnick RB, Galanter M, Pycha C, Cohen A, Grandison P, Flood N (1992) Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacol Bull 28 /1: 109–113
Strain EC, Preston KL, Liebson IA, Bigelow GE (1992) Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 261 /3: 985–993
Blaine JD (1992) Buprenorphine: an alternative treatment for opioid dependence. NIDA Res Monogr 121: 1–4
Marion IJ (1955) LAAM in the treatment of opiate addiction. Treatment improvement protocol (TIP), vol 22, US Department of Health and Human Services Washington DC
Ling W, Rawson RA, Compton MA (1994) Substitution pharmacotherapies of opioid addiction from methadone to LAAM and buprenorphine. J Psycho Drugs 26: 119–128
Verebey K, Volavka J, Mule SJ, Resnik RB (1976) Naltrexone: Disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 20: 315–328
Eberlein HJ (1982) Narkose nach Heroinentzug. Dtsch Med Wochenschr 107: 1819
Freye E (1992) Die perioperative Behandlung des Arzneimittelabhängigen. Anästh Intensiv med 3: 59–67
Giuffrida JG, Bizzari DV, Saure AC, Sharoff RL (1970) Anesthetic management of drug abusers. Anesth Analg 49: 272–278
Eismann B, Lam RC, Rush B (1964) Surgery in the narcotic addict. Ann Surg 159: 748–759
Rapp SE, Ready LB, Nessly ML (1995) Acute pain management in patients with prior opioid consumption: a case.- controlled retrospective review. Pain 61: 195–201
Hughes JR, Bickel WK, Hggins ST (1991) Buprenorphine for pain relief in a patient with drug abuse. Am J Drug Alcohol Abuse 17 /4: 451–455
Gelfand ML, Hammer H, Hevizy J (1967) Asymptomatic pulmonary atelactasis in drug addicts. Dis Chest 53: 782–786
Bschor F (1987) Zur Revision des Abstinenzparadisgmas in der Behandlung Sucht kranker. Ambulante, medikamen-tengestützte Therapie, ein möglicher ärztlicher Beitrag zur AIDS-Prävention. Dtsch Med Wochenschr 112: 907
Singarajah C, Lavies NG (1992) An overdose of ecstasy. Anaesthesia 47: 686–687
Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (»ectasy«). Lancet 340: 384–387
Dowling GP, McDonough ET, Bost RO (1987) »Eve« and »ecstasy«: A report of five deaths with the use of MDEA and MDMA. JAMA 257: 1615–1617
Gouzoulis E, Borchardt D, Hermle L (1993) A case of toxic psychosis induced by »Eve« (3,4-methylenedioxyethyl-amphetamine). Arch Gen Psychiatry 50: 75
Manchada S, Conolly MJ (1993) Cerebral infraction in association with ecstasy. Postgrad Med J 69: 874–875
Freye E (1997) Kokain, Ecstasy und verwandte Designerdrogen - Wirkungsweise, Überdosierung, therapeutische Notfallmaßnahmen. Barth, Heidelberg Leipzig
Täschner KL (1994) Drogen und Straßenverkehr. Dtsch Ärzte Z 35
Külpmann WR. Feststellung des Beigebrauchs bei der Methadon-Substitutions behandlung von i.v.-Heroinabhängigen. Dtsch Ärztebl 1994 2: C-149-C-151
Baselt RC (1982) Disposition of toxic drugs and chemicals in man, 2nd Edn. Davis Biomedical Publ, Philadelphia
Hawks RL, Chiang CN (1986) Urine testing for drugs of abuse. US Department of Health and Human Servivces (NIH), Rockville/MD Maryland, NIDA Research Monograph Series, vol 73
Blum K (1984) Handbook of abusable drugs. Gardner, New York
Ladewig D, Stohler L (1994) Das Opiatentzugssyndrom–Skalierung und medikamentöse Strategien. In: Tretter F, Busello-Spieth W, Bender WH (Hrsg) Therapie von Ent-zugssyndromen. Springer, Berlin Heidelberg New York Tokio, pp 144–168
Loimer N, Schmid RW, Presslich O, Lenz K (1989) Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment. J Psychiatr Res 23: 81–86
Loimer N, Lenz K, Schmid R, Presslich O (1991) Technique for greatly shortening the transition from methadone to naltrexone maintenence of patients addicted to opiates. Am J Psychiat 148: 933–935
Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21: 253–259
Legarda L, Gossop H (1994) A 24 hour inpatient detoxification treatment for heroin addicts: a preliminary investigation. Drug Alcohol Depend 35: 91–93
Tretter F (1996) Von der Phantasie, die Sucht auszuschlafen. MMW 138: 76–77
Tretter F, Burkhardt D, Buzello-Spieth S, Reiss J, Walcher S, Büchele W (1996) Anwendungsverfahren mit dem forcierten Opiatentzug in Narkose. MMW 138: 787–791
Reiss J (1996) Drogenentzug unter Narkose–Eine Konsequenz der Substitutionstherapie. Fortschr Med 24: 12–13
Klienbaum P, Thürauf N, Michel MC, Scherbaum N, Gaspar M, Peters J (1998) Profound increase in epinephrine in plasma and cardiovascular stimulation after p-opiate receptor blockade in opiate addicted patients during barbiturate-induced anesthesia for acute detoxyfication. Anesthesiology 88: 1154–1161
Glen JB (1998) The development of »Diprifusor«: a TCI system for propofol. Anaesthesia S3: 13–21
Charney DS, Heninger GR, Kleber HD (1986) The combined use of Clonidine and naltrexone a rapid, safe, and effective treatement of abrupt withdrawal from methadone. Am J Psychiatry 143 /7: 831–837
Vining DH, Kosten TR, Kleber HD (1988) Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 63: 567–575
Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T (1987) Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse 13/1, 2: 1–17
Ghignone M (1987) Effects of Clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. Anesthesiology 67: 3–10
Engelman E, Lipzyc M, Gilbert E et al. (1989) Effects of Clonidine on anesthetic requirements and hemodynamic response during aortic surgery. Anesthesiology 71: 178–187
Wilcox GL, Carlson GH, Joachim A, Jurna I (1987) Mutual potentiation of antinociceptive effects of morphine and Clonidine on motor and sensory responses in rat spinal cord. Brain Res 405: 84–93
Redmond DE, Hwang YH (1982) The primate locus coeru-leus and affects of Clonidine on opiate withdrawal. J Clin Psychiatry 43: 25–31
Foote SL, Bloom FE, Aston-Jones G (1983) Nucleus locus ceruleus: New evidence for anatomical and physiological specificity. Physiol Rev 63: 844–895
Jarrot B, Conway EL, Maccarone C, Lewis SJ (1987) Clonidine: understanding its disposition, sites and mechanism of action. Clin Exp Pharmacol Physiol 14: 471–479
Freye E (1999) Elektroenzphalograpie, spinal und morto-risch evozierte Potentiale. In: Jantzen JP, Löffler W (Hrsg) Neuroanästhesie. Thieme, Stuttgart, pp 155–191
Sigl JC, Chamoun NG (1994) An introduction to bispectral analysis for the EEG. J Clin Monit 10: 392–404
Freye E, Grabitz K, Sandmann W (1996) Was bringt die 3. Generation im Neuro monitoring für die klinische Praxis? Anästhesiol Intensivmed 3: 120–127
Blumberg H, Dayton HB (1974) Naloxone, naltrexone, and related noroxymorphones. In: Braude MC, Harris LS, Smith MJP, Villareal JE (eds) Narcotic antagonists. Raven, New York (Adv Biochem Psychopharm) vol 8, pp 33–43
Martin WR, Jasinski DR, Mansky PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 28: 784–791
Smith TC (1979) Comparison of naloxone and naltrexone in man. Anesthesiology 51: S 573
Jenkins SA (1996) Somatostatin and octreotide. Medi-media Asia, Hong Kong
North RA, Williams JT (1975) Enkephalines inhibit fireing of myenteric neurons. Nature 246: 460
Takeda T, Taniyama K, Baba S, Tanaka C (1989) Putative mechanisms involved in excitatory and inhibitory effects of somatostatin on intestinal motility. Am J Physiol 257: G 532-G 538
Williams J, North RA (1978) Inhibition offirering of myenteric neurones by somatostatin. Brain Res 155: 165–168
Gagniella TS, O’Dorisio TM, Fassler JE, Mekhjian HS (1990) Treatment of endocrine and nonendocrine secretiory diarrheal states with Sandostatin®. Metabolism 39: 172–175
Sehppard M, Shapairo B, Berelowitz M, Pimstone B (1979) Metabolic clearance and plasma half dissapearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48: 50–53
Klepstad P, Maurset A, Moberg ER, Oye I (1990) Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 187: 513–518
Irifune M, Shimizu M, Nomoto M, Fukuda T (1992) Keta-mine induced anesthesia involves the N-methyl-D-aspar-tate receptor-channel complex in mice. Brain Res 569: 1–9
Monaghan DT, Bridges RJ, Cotman CW (1989) The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29: 365–462
Katz J, Kavanagh BP, Sandler AN (1992) Preemptive analgesia: clinical evidence of neuroplasticity contributing to postoperative pain. Anesthesiology 77: 439–446
Arner S, Meyerson BA (1988) Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 33: 11–23
Dickenson AH. Neurophysiology of opioid poorly responsive pain. Cancer Surv 1995 21: 5–16
Brown JP, Boden P, Singh L, Gee NS (1996) Mechanimss of action of gabapentin. Rev Contemp Pharmacother 7: 203–214
Field MJ, Oles RJ, Lewis AS, McVlerary S, Hughes J, Singh L (1997) Gabapentin (neurontin) and S(f)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121: 1513–1522
Mellik GA, Larry DO, Mellik B (1997) Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Reha-bil 78: 98–105
Rosner H, Rubin L, Kestenbaum A (1996) Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 12: 56–58
Sandyk R (1992) L-tryptophan in neuropsychiatric disorders: a review. Intern J Neurosci 67: 127–144
Raffa RB, Friedrichs E, Reimann W, Shank RP, Codd EE, Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an »atypical« opioid analgesic. J Pharmacol Exp Ther 260 /1: 275–285
Sandyk R, Fisher H (1988) Serotonin in involuntary movement disorders. Intern J Neurosci 42: 185–205
Sandyk R (1986) L-tryptophan in the treatment of restless legs syndrome. Am J Psychiatry 143: 554–555
Cucchia AT, Monnat M, Spagnoli J, Ferrero F, Bertschy G (1998) Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long term results. Drug Alcohol Depend 52: 243–250
Yamaguchi K, Anderson JM (1992) Biocompatibility studies of naltrexone sustained release fomulations. J Cont Rel 19: 299–314
Tefft JA, Roskos KV, Heller J (1992) The effect of lipase on release of naltrexone from triglycxeride-coated celllulose acetate phtalate micropheres. J Biomed Material Res 26: 713–724
Holaday JW, Tortella FC (1984) Multiple opioid receptors: Possible physiological functions of m and 5 binding sites in vivo. In: Genazzini AR, Muller EE (eds) Central and peripheral endorphins: Basis and clinical aspects. Raven, New York, pp 237–250
Martin WR (1981) Mini-Symposium II. Multiple opioid receptors. Life Sci 28: 1547–1554
Schmidhammer H, Smith CFC, Erlach D et al. (1990) Synthesis and biological evaluation of 14-Alkoxymorphinans. 3. Extensive study on cyprodime-related compounds. J Med Chem 33: 1200–1206
Kaiser C, Pontecorvo MJ, Mewshaw RE (1991) Sigma receptor ligands: function and activity. Neurotransmissions 7 /1: 1–5
Takemori AE, Sofuoglu M, Sultana M, Nagase H, Porto-ghese PS (1990) Pharmacology of highly selective, non-peptide delta opioid receptor antagonists. In: van Ree JM, Mulder AH, Wiegant VM, van Wimersma Greidanus TB (eds) New leads in opioid research. Excerpta Medica, Amsterdam New York (International congress series), vol 914, pp 277–278
Romer D, Buscher H, Hill RC et al. (1980) Bremazocine: A potent, long-acting opiate kappa-agonist. Life Sci 27: 971–978
Buzas B, Toth G, Cavagnero S, Hruby VJ, Borsodi A (1992) Synthesis and binding characteristics of the highly delta-specific new tritiated opioid peptide [3H]deltorphin II. Life Sci 50: PL 75-PL 77
Rossier JT, Vargo M, Minick S, Ling N, Bloom EF, Guillemin R (1977) Regional dissociation of (3-endorphin and enkephalin contents in rat brain and pituitary. Proc Natl Acad Sci USA 74: 5262–5165
Frederickson RCA, Geary LE (1982) Endogenous opioid peptides: Review of physiological, pharmacologiocal and clinical aspects. Prog Neurobiol 19: 16–69
Smith TW, Hughes J, Kosterlitz HW, Sosa RP (1976) Enkephalins: Isolation, distribution and function. Opiates and endogenous opioid peptides. Elsevier, Amsterdam
Feurle GE, Helmstaetter V, Weber U (1982) Met-and Leu-enkephalin immuno-and bio-reactivity in human stomach and pancreas. Life Sci 31: 2961–2969
Kabayashi ST, Ushida T, Ohashi T et al. (1991) Met-eneke-phalin-Arg-Gly-Leu-like immunoractivity in adrenal chromaffin cells and carotid body chief cells of the dog and monkey. Biomed Res 4: 201–210
De Wald D, Lewis RV (1983) Enkephalin-containing polypeptide levels in normal tensive and SH rat adrenal glands. Peptides 4: 121–123
Maysinger D, Hollt v, Seizinger BR, Mehraein P, Pasi A, Herz A (1982) Parallel distribution of immunoreactive alpha-neoendorphin and dynorphin in rat and human tissue. Neuropeptides 2: 211–225
Czlonkowski A, Costa T, Przewlocki A, Pasi A, Herz A (1983) Opioid receptor binding in human spinal cord. Brain Res 267: 392–396
Watson SJ, Akil H, Ghazarsson VE, Goldstein A (1981) Dynorphin immunocytochemical localization in brain and peripheral nervous system: prelimary studies. Proc Natl Acad Sci USA 78: 1260–1263
Watson SJ, Khachaturian H, Akil H, Coy DH, Goldstein A (1982) Comparison of the distribution of dynorphin system and enkephalin system in brain. Science 218: 1134–1136
Feuerstein G, Molineaux CJ, Rosensberg JG, Faden AD, Cox BM (1983) Dynorphin and Leu-Enkephalin in brain nuclei and pituitary of WKY and SHR rats. Peptides 4: 225–229
Höckfelt T, Ljungdahl A, Terenius I, Eide R, Nilsson G (1977) Immunohistochemical analysis of peptide pathways possibly related to pain and analgesia: enkephalin and substance P. Proc Natl Acad Sci USA 74: 3081
Bruni JF, van Vugt D, Marschall S, Meilers J (1977) Effect of naloxone, morphine, methionine-enkephalin on serum prolactin, lutenizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. Life Sci 21: 461
Dupont A, Cusan L, Garon L, Labrie F, Li H (1977) ß-Endor-phin. Stimulation of growth hormone release in vivo. Proc Natl Acad Sci USA 74: 358
Shaar CJ, Frederickson RCA, Dinninger NB, Jackson L (1977) Enkephalin analogues and naloxone modulate the release of growth hormone and prolactin. Evidence for regulation by an endgenous opioid peptide in brain. Life Sci 21: 853
Copolov DL, Helme RD (1983) Enkephalins and Endorphins Clinical, pharmacological and therapeutic implications. Drugs 26: 503–519
Akil H, Richardson DE, Barchas JD, Li CH (1978) Appearance of ß-enorphin-like immunoreactivity in human ventricular cerebropinal fluid upon electrical stimulation. Proc Natl Acad Sci USA 75: 5170–5172
Hosobuchi Y, Adams JE, Lichnitz R (1977) Pain relief by electrical stimulation of the central gray matter in humans and its reversal by naloxone. Science 197: 183
yama T, Jin T, Yamaha R (1980) Profound analgesic effects of ß-endorphin in man. Lancet I: 122–124
Genazzini AR, Nappi G, Facchinetti F et al. (1984) Progressive impairment of CSF ß- EP levels in migraine sufferers. Pain 18: 127–133
Sicuteri F, Anselmi B, Curradi C, Michelacci S, Sassi A (1978) Morphine-like factors in CSF headache suffers. In: Costa E, Trabucchi M (eds) Adv Biochem Psychopharm, vol 18. Raven, New York, pp 363–366
Sicuteri F (1979) Headache as the most common disease of the antionociveptive system: analogies with morphine abstinence. In: Bonica JJ (ed) Advances in pain research and therapy, vol 3. Raven, New York, pp 359–365
Sicuteri F, Fanciullacci M, Michelacci S (1978) Decentratil-sation supersensitivity in headache and central panalge-sia. In: Friedman AP, Granger ME, Critchley M (eds) Clinical studies on headache, vol 6. Karger, Basel, pp 19–33
Seymour D (1993) Double-blind, placebo-controlled efficacy study of Stadol(HNS (transnasal butorphanol) and intramuscular methadone in the acute treatment of migraine. 7th World Congress of Pain. ISAP Publications, Paris
Couch J, Diamond D, Elkind A et al. (1993) Evaluation of the efficacy and safety of StadoTNS (transnasal butorphanol) in the treatment of acute migraine in outpatients. 7th World Congress on Pain. ISAP Publications, Paris
Symons IE, Emons PC, Farman JV (1982) Endogenous opioid poisoning? Br Med J 284: 469–470
Cohen M, Pickar D, Dubois M (1982) Role of the endogenous opioid system in the human stress response. Psychiatry Clin North Am 6: 457
Miralles FS, Olaso MJ, Fuentes T, Lopez T, Laorden ML, Puig MM (1983) Presurgical stress and plasma endorphin levels. Anesthesiology 59: 366–367
Laorden ML, Miralles F, Fuentes T, Lopez F, Cantera M (1984) Effects of stresstherapy on plasma beta-endorphin-like immunorectivity. Meth and Find Expl Clin Pharmacol 6: 671–674
Hynynen M, Lethinen A-M, Salmenperä M, Fyhrquist F, Takkunen O, Heinonmen J (1986) Continuous infusion of fentanyl or alfentanil for coronary artery surgery-Effects on plasma Cortisol concentration, ß-endorphin immuno-reactivity and arginine vasopressin. Br J Anaesth 58: 1260–1266
Kanwal JS, Anand MB (1986) The stress response to surgical trauma: From physiological basis to therapeutic implications. Prog Food Nutr Sei 10: 67–123
Bloom F, Segal D, Ling N, Guillemin R (1976) Endorphins: profound behavioral effects in rats suggests new etiological factors in mental illness. Science 194: 630–632
Günne LM, Lindström L, Terenius L (1977) Naloxone-induced reversal of schizophrenic halluzinations. J Neural Transm 40: 15
Schenk GK, Enderes P, Engelmeier MP et al. (1978) Application of morphine antagonist naloxone in psychic disorders. Arzneimittelforsch/Drug Res 28: 1274–1277
Kline NS, Li CH, Lehmann E, Lajtha A, Laski E, Copper T (1977) ß-Endorphin induced changes in schizophrenic and depressed patients. Arch Gen Psychiatry 34: 1111
Van Ree JM, Otte AP (1980) Effects of ( Des-Tyr)- y-endorphin and ß-endorphin as compared to haloperidol and amphetamine on nucleus accumbens self-stimulation. Neuropharmacology 19: 429–434
Van Ree JM (1986) Role of pituitary and related neuropeptides in alcoholism and pharmacodependence. Prog Neu-ropsychopharmacol Biol Psychiatr 10: 219–228
Akil H, Watson SJ, Young E (1984) Endogenous opioids. Biology and function. Ann Rev Neurosci 7: 223–255
Kennedy SH, Goldbloom DS (1991) Current perspectives on drug therapies for anorexia nervosa and bulemia nervosa. Drugs 41 /3: 367–377
Spiegel TA, Stunkard AJ, Shrager WE, O’Brien CP, Morrison MF, Stellar E (1987) Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav 40 /2: 135–141
de Zwaan M, Mitchell JE (1992) Opiate antagonists and eating behavior: a review. J Clin Pharmacol 32 /12: 1060–1072
Shaw WN, Mitch CH, Leander JD, Mendelsohn LG, Zimmerman DM (1991) The effect of the opioid antagonist LY 255–582 on body weight of the obese Zucker rat. Int J Obes Relat Metab Disord 15 /6: 387–395
Sandyk R (1988) Naltrexone suppresses abormal sexual behaviour in tourette’s syndrome. Int J Neurosci 43/1–2: 107–110
Sandman CA (1988) (3-Endorphin dysregulation in autistic and self-injurious behavior. A neurodevelopmental hypothesis. Synapse 2/3: 93–199
Campbell M, Anderson LT, Small AM, Locascio JJ, Lynch NS, Choroco MC (1990) Naltrexon in autistic children: a double-blind and placebo-controlled study. Psycho-pharmacol Bull 26 /1: 130–135
Tseng LF, Loh HH, Li CH (1976) (3-Endorphin: Cross tolerance and cross physical dependance on morphine. Proc Natl Acad Sci USA 73: 4187
Wei E, Loh HH (1976) Physical dependance on opiate-like peptides. Science 193: 1262
Belluzzi JD, Stein L (1977) Enkephalin may mediate euphoria and drive-reduction reward. Nature 266: 556
Dingledine R, Valentino RJ, Bostock E, King ME, Chang KJ (1983) Down-regulation of the 5- but not (j-opioid receptors in the hippocampal slice aassiociated with loss of physiological response. Life Sci 33: 333–336
Tao P-L, Chang L-R, Law PY, Loh HH (1988) Decrease in 5-opioid receptor density in rat brain after chronic (D-Ala2,D-Leu5) enkephalin treatment. Brain Res 462: 313–320
Dole VP, Nyswander M (1967) Heroin addiction - a metabolic disease. Arch Intern Med 120: 19
Abdelhamid EE, Sultana PM, Portoghese PS, Takemori AE (1991) Selective blockade of the delta opioid receptor prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther 258: 299–303
Lee PHK, McNutt R, Chang K-J (1992) A nonpeptide delta-opioid receptor antagonist BW373U96, supppresses nalo-xone-precipitated morphine abstinence. Proceedings International Narcotic Research Conference (INRC), Key-stone/CO, USA
D’Amato RJ, Holaday JW (1984) Multiple opiate receptors in endotoxic shock: Evidence for 5 involvement and p-5 interactions in vivo. Proc Natl Acad Sci USA 81: 2898–2901
Long JB, Ruvio BA, Holaday JW (1984) ICI 174,864, a novel delta antagonist, reverses endotoxic shock: Pretreatment with dynorphin (1–13) a kappa agonist, blocks this therapeutic effect. Neuropeptides 5: 292–294
Hamilton AJ, Carr DB, La Rovere JM, Black PM (1986) Endotoxic shock elicits greater endorphin secretion than hemorrhage. Circ Shock 19: 47–54
Malcolm DS, Zaloga GP, Willey SC, Amir S, Holaday JW (1988) Naloxone potentiates epinephrine’s pressor action in endotoxemic shock. Circ Shock 25: 259–265
Holaday JW, D’Amato RJ, Ruvio BA, Feuertein G, Faden Al (1983) Adrenalectomy blocks pressure responses to naloxone in endotoxic shock. Circ Shock 11: 201–210
Malcolm DS, Zaloga GP, Willey SC, Amir S, Holaday JW (1988) Naloxone potentiates epinephrine’s pressure actions in endotoxemic rats. Circ Shock 25: 259–265
Xu T, Wang T, Han J (1992) Involvement of opioid receptors in nucleus tractus solitarii in modulating endotoxic hypotension in rats. Neurosci Lett 146 /1: 72–74
Curtis MT, Lefer AM (1982) Beneficial action of a new opiate antagonist (Win 44,441–3) in hemorrhagic shock. Eur J Pharmacol 78: 307–313
Feuerstein G, Faden Al, Krumins SA (1984) Alteration in opiate receptors binding after hemorrhagic shock. Eur J Pharmacol 100: 245–246
Paciorek PM, Todd MH (1982) Comparison of the cardiovascular effects of meptazinol and naloxone following anaphylactic shock in anaesthetized rats. Br J Pharmacol 76: 245 P
Amir S (1983) Antianaphylactic effect of naloxone in mice is mediated by increased central sympathetic outflow to sympathetic nerve endings and adrenal medulla. Brain Res 274: 180–183
Holaday JW, Faden Al (1980) Naloxone acts at central opiate receptors to reverse hypotension, hypothermia, and hypoventilation in spinal shock. Brain Res 75: 295–300
Faden Al, Jacobs TP, Zivin JA. Comparison of naloxone and a delta-selective antagonist in experimental spinal »stroke«. Life Sci 1983 33: 707–710
Faden Al (1983) Opiate antagonist in the treatment of stroke. Current concepts in cerebrovascular disease. Stroke 18: 27–31
Groeger JS (1986) Opioid antagonists in circulatory shock. Crit Care Med 14: 170–171
Wybran J (1985) Enkephalins and endorphins as modifiers of the immune system: present and future. Fed Proc 44: 92–94
Mathews PM, Froelich CJ, Sibbitt JWL, Brankhurst AD (1983) Enhancement of natural cytotoxicity by (3-endor-phin. J Immunol 130: 1658–1662
Gilman SC, Schwartz JM, Milner RJ, Bloom FE, Feldman JD (1982) (3-Endorphin enhances lymphozyte proliferative responses. Proc Natl Acad Sci USA 79: 4226–4230
Bryant HU, Bernton EW, Holaday JW (1988) Immunosuppressive effects of chronic morphine treatment in mice. Life Sci 41: 1731–1738
Yeager MY, Yu CT, Campbell AS, Moschella M, Guyre PM (1992) Effect of morphin and (3-endorphin on human Fc receptor-dependant and natural killer cell functions. Clin Immun Immunpath 62 /3: 336–343
Fiatarone MA, Morley JE, Bloom EE, Benton D, Makinodan T, Salomon GF (1988) Endogenous opioids and the exercise -induced augmentation of natural killer cell activity. Lab Clin Med 112: 552–554
Palm S, Lehzen S, Mignat C, Steinmann J, Leimenstoll G, Maier G (1998) Does prolonged oral treatment with sustained-release morphine tablets influence immune function? Anesth Analg 86: 166–172
Carr DJJ (1991) Minireview: The role of endogenous opioids and their receptors in the immune system. Soc Expt Biol Med 37: 710–720
Hamel U, Kielwein G, Teschemacher H (1985) p-Casomor-phin immunoreactive material in cows milk incubated with various bacterial species. J Dairy Res 52: 139–148
Teschemacher H, Brantl V, Henschen A, Lottspeich F (1990) p-Casomorphin-(3-casein fragments with opioid activity: Detection and structure. In: Nyberg F, Brantl V (eds) (3-Casomorphin and related peptides. Fyris-Trych AB, Uppsala, pp 9–14
Volterra A, Restani P, Brunello N, Galli CL, Racagni G (1986) Interaction of ß-casomorphins with multiple opioid receptors: In vitro and in vivo studies in the newborn rat brain. Dev Brain Res 30: 25–30
Ramabadran K (1988) Sudden infant death syndrome and opioid peptides. Am J Dis Child 142: 12–13
Schusdziarra V, Schick A, de la Fuente A et al. (1983) Effect of ß-casomorphins and analogs on insulin release in dogs. Endocrinology 112: 885–889
Lindström LH, Lyrenäs S, Nyberg F, Terenius L (1990) ß-Casomorphins in postpartum psychosis. In: Nyberg F, Brantl V (eds) ß-Casomorphins and related peptides. Fyris- Tryck AB, Uppsala, pp 157–162
Kreis GJ (1986) Physiological role of somatostatin in the digestive tract: gastric secretion, intestinal absorption, and motility. Scand J Gastroenterol 21: 47–53
Goldstein DB, Goldstein A. Possible role of enzyme inhibition and repression in drug tolerance and addiction. Biochem Pharmac 1961 8: 48–53
Teschemacher H (1987) Opioidrezeptoren und Opioid-peptide. Pharm Z 10: 556–567
Siegfried J (1988) Electrostimulation and neurosurgical measures in cancer pain. Springer, Berlin Heidelberg New York Tokio (Recent Results in Cancer Research), vol 108, pp 28–32
Meynadier J, Dalmas S, Lecomte JM, Gros CI, Schwartz JC (1989) Potent analgesic effect of inhibitors of enkephalin metabolism administered intrathecal to cancer patients. Pain Clin 4 /2: 201–205
Oye B (1985) Medikamentöse Schmerztherapie. Wiss. Buchverlag Dr. Peter Nietsch, Weiler/Bingen
Teschemacher H, Schweigerer L (1985) Opioid preptides: do they have immunological significance? Trends Pharmacol Sci 6: 368–370
Jasinski DR, Pevnik JS, Griffith JD (1978) Human pharmacology and the abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35: 501–516
Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs. In: Martin WR (ed) Drug addiction, vol 1. Springer, Berlin Heidelberg New York, pp 197–258
Lewis JW, Walter D (1992) Buprenorphine–background to its development as a treatment for opioid dependence. NIDA Research Monograph Series 121, pp 5–11
Zola EM, MacLeod DC (1983) Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intell Clin Pharm 17: 411–417
Cookson RF (1983) Carfentanil and Lofentanil. Clin Anaesthesiol 1: 156–158
Keup W (1983) Clonidin–seine Möglichkeiten in der Pharmakotherapie der Heroin abhängigkeit. Dtsch Ärztebl 80 /3: 25–32
Seevers MH (1972) Characteristics of dependence on and abuse of psychoactive drugs. In: Mule SJ, Brill H (eds) Chemical and biological aspects of drug dependence, vol 2. CRC Press, Cleveland, pp 13–21
Kaiser C, Pontecorvo MJ, Mewshaw RE (1991) Sigma receptor ligands: function and activity. Neurotransmissions 7 /1: 1–5
Holaday JW, Tortella FC (1984) Multiple opioid receptors: Possible physiological functions of jj and 5 binding sites in vivo. In: Genazzini AR, Müller EE (eds) Central and peripheral endorphins: Basis and clinical aspects. Raven, New York, pp 237–250
Martin WR (1981) Mini-Symposium II. Multiple opioid receptors. Life Sei 28: 1547–1554
Schmidhammer H, Smith CFC, Erlach D et al. (1990) Synthesis and biological evaluation of 14-Alkoxymorphinans. 3. Extensive study on cyprodime-related compounds. J Med Chem 33: 1200–1206
Römer D, Büscher H, Hill RC et al. (1980) Bremazocine: A potent, long-acting opiate kappa-agonist. Life Sei 27: 971–978
Buzas B, Toth G, Cavagnero S, Hruby VJ, Borsodi A (1992) Synthesis and binding characteristics of the highly delta-specific new tritiated opioid peptide [3H]deltorphin II. Life Sei 50: PL 75-PL 77
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Freye, E. (2004). Der opiatabhängige Patient. In: Opioide in der Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09096-1_33
Download citation
DOI: https://doi.org/10.1007/978-3-662-09096-1_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-09097-8
Online ISBN: 978-3-662-09096-1
eBook Packages: Springer Book Archive